Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial hypertension drug trial. Winrevair is the first activin-signaling inhibitor therapy ...

Merck (NYSE:MRK) experienced a 13% increase in its stock price over the last month, aided by several significant developments. The company's upcoming presentations at the American College of ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...

Merck , known as MSD outside of the United States and Canada, today announced that new clinical and outcomes research data will be presented at the American College of Cardiology's Annual Scientific ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

which scientists think could lead to a partial reversal of the disease process in PAH. MSD – known as Merck & Co in the US and Canada – has predicted sales of the drug could reach upwards of $ ...

Keytruda's sales were $29.5 billion, up 18% year over year; the drug accounted ... 1 candidate. Merck's own newer medicines, like Winrevair, a treatment for pulmonary arterial hypertension ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Merck's stock recently got a cardio boost, jumping 13% in a month thanks to some pulse-quickening developments. The company ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...